Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 35

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 35
---
 for the ten-trading day period ending on (and including) the trading day preceding the date on which Enfusion Stockholders access this information will be available by 4:30 p.m., New York City time, at https://investors.clearwateranalytics.com and can also be obtained

18

by contacting Innisfree at the address and telephone number listed in this Proxy Statement/Prospectus. Provided that all conditions to the consummation of the Transactions are satisfied, we expect that the Transactions will close two business days after the Enfusion Stockholders vote to approve the Transactions at the Special Meeting. The Special Meeting(see page 45) Purposes of the Special Meeting At the Special Meeting, Enfusion Stockholders will be asked to vote upon the following proposals:

| • |     | The Merger Agreement Proposal; and |

| • |     | The Adjournment Proposal. |

Record Date The record date for the determination of stockholders entitled to notice of and to vote at the Special Meeting is March 20, 2025. Only Enfusion Stockholders who held shares of record as of the close of business on the record date are entitled to receive notice of and to vote at the Special Meeting and any adjournment or postponement of the Special Meeting, as long as such shares remain outstanding on the date of the Special Meeting. Enfusion’s official stock ownership records will conclusively determine whether a stockholder is a “holder of record” as of the record date. Required Vote

| • |     | Proposal 1—The Merger Agreement Proposal. The affirmative vote, virtually or by proxy, of holders of                                                                                                             
 at least a majority of the outstanding shares of Enfusion Common Stock and Enfusion Class B Common Stock entitled to vote on the Merger Agreement Proposal is required to approve the Merger Agreement Proposal. |

| • |     | Proposal 2—The Adjournment Proposal. The affirmative vote, virtually or by proxy, of a majority of                                                                                          
 the votes properly cast by holders of shares of Enfusion Common Stock and Enfusion Class B Common Stock represented at the Special Meeting is required to approve the Adjournment Proposal. |

As of the record date, Enfusion directors and executive officers, as a group, owned and were entitled to vote 46,887,683 shares of Enfusion Common Stock and Enfusion Class B Common Stock, or approximately 36.1% of the outstanding shares of Enfusion Common Stock and Enfusion Class B Common Stock. Enfusion currently expects